Literature DB >> 6961420

Mucolipidosis III is genetically heterogeneous.

N K Honey, O T Mueller, L E Little, A L Miller, T B Shows.   

Abstract

Mucolipidosis III (ML III), or pseudo-Hurler polydystrophy, is an inherited childhood disorder characterized biochemically by low activities and abnormal electrophoretic patterns of multiple lysosomal enzymes in fibroblasts. The primary deficiency of ML III has been proposed to be in UDP-N-acetylglucosamine:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. However, variation in this enzyme and in other biochemical properties of different ML III lines has been observed. Therefore, we investigated genetic heterogeneity within the disorder by complementation analysis. Heterokaryon cell fractions were generated by fusing together ML III fibroblast lines. When pairs of cells complemented, correction of lysosomal enzyme activities and electrophoretic patterns was observed. Twelve fibroblast lines from 10 sibships were analyzed and three distinct complementation groups were characterized. One complementation group represents the classical ML III disorder. A single cell line identifies a second complementation group. The cell lines comprising a third complementation group have a number of biochemical characteristics different from classical ML III and may represent a genetically distinct disorder.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6961420      PMCID: PMC347351          DOI: 10.1073/pnas.79.23.7420

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Leroy's l-cell disease: markedly increased activity of plasma acid hydrolases.

Authors:  W R Den Tandt; E Lassila; M Philippart
Journal:  J Lab Clin Med       Date:  1974-03

2.  Physicochemical modifications of lysosomal hydrolases during intracellular transport.

Authors:  A Goldstone; H Koenig
Journal:  Biochem J       Date:  1973-02       Impact factor: 3.857

3.  Early events in the biosynthesis of the lysosomal enzyme cathepsin D.

Authors:  A H Erickson; G Blobel
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

4.  Urinary lysosomal hydrolases in mucolipidosis II and mucolipidosis III.

Authors:  B C Kress; A L Miller
Journal:  Biochem J       Date:  1979-02-01       Impact factor: 3.857

5.  Mucolipidosis II and III: different residual activity of beta-galactosidase in cultured fibroblasts.

Authors:  J G Leroy; J S O'Brien
Journal:  Clin Genet       Date:  1976-05       Impact factor: 4.438

6.  Dimethyl sulfoxide enhances polyethylene glycol-mediated somatic cell fusion.

Authors:  T H Norwood; C J Zeigler; G M Martin
Journal:  Somatic Cell Genet       Date:  1976-05

7.  Mucolipidosis III (pseudo-Hurler polydystrophy): Clinical and laboratory studies in a series of 12 patients.

Authors:  T E Kelly; G H Thomas; H A Taylor; V A McKusick; W S Sly; J H Glaser; M Robinow; L Luzzatti; C Espiritu; M Feingold; M J Bull; E M Ashenhurst; E J Ives
Journal:  Johns Hopkins Med J       Date:  1975-10

8.  [Three cases of mucolipidosis type III (author's transl)].

Authors:  J Torreblanca; M C Antelo; S García García; J García Consuegra; F Collado
Journal:  An Esp Pediatr       Date:  1979-02

9.  Acid acylhydrolase deficiency in I-cell disease and pseudo-Hurler polydystrophy.

Authors:  R C Pittman; J C Williams; A L Miller; D Steinberg
Journal:  Biochim Biophys Acta       Date:  1979-12-18

10.  Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts.

Authors:  A Kaplan; D T Achord; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

View more
  15 in total

1.  The natural history and osteodystrophy of mucolipidosis types II and III.

Authors:  Grace David-Vizcarra; Julie Briody; Jenny Ault; Michael Fietz; Janice Fletcher; Ravi Savarirayan; Meredith Wilson; Jim McGill; Matthew Edwards; Craig Munns; Melanie Alcausin; Sara Cathey; David Sillence
Journal:  J Paediatr Child Health       Date:  2010-03-29       Impact factor: 1.954

2.  Lack of complementation in somatic cell hybrids between fibroblasts from patients with different forms of cystinosis.

Authors:  O L Pellett; M L Smith; A A Greene; J A Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

Review 3.  Molecular analysis of the GlcNac-1-phosphotransferase.

Authors:  T Braulke; S Pohl; S Storch
Journal:  J Inherit Metab Dis       Date:  2008-04-15       Impact factor: 4.982

4.  Altered molecular size of N-acetylglucosamine 1-phosphotransferase in I-cell disease and pseudo-Hurler polydystrophy.

Authors:  Y Ben-Yoseph; M Potier; D A Mitchell; B A Pack; S B Melançon; H L Nadler
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

Review 5.  Trafficking of lysosomal enzymes in normal and disease states.

Authors:  S Kornfeld
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

6.  Molecular size of N-acetylglucosaminylphosphotransferase and alpha-N-acetylglucosaminyl phosphodiesterase as determined in situ in Golgi membranes by radiation inactivation.

Authors:  Y Ben-Yoseph; M Potier; B A Pack; D A Mitchell; S B Melançon; H L Nadler
Journal:  Biochem J       Date:  1986-05-01       Impact factor: 3.857

7.  A variant of mucolipidosis. II. Clinical, biochemical and pathological investigations.

Authors:  L Poenaru; L Castelnau; F Tome; J Boue; P Maroteaux
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

8.  The effects of sucrose loading on lysosomal hydrolases.

Authors:  T Kato; S Okada; T Yutaka; H Yabuuchi
Journal:  Mol Cell Biochem       Date:  1984       Impact factor: 3.396

9.  Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC)

Authors:  A Raas-Rothschild; V Cormier-Daire; M Bao; E Genin; R Salomon; K Brewer; M Zeigler; H Mandel; S Toth; B Roe; A Munnich; W M Canfield
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

10.  An atypical form of mucolipidosis III.

Authors:  P Freisinger; J C Padovani; P Maroteaux
Journal:  J Med Genet       Date:  1992-11       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.